1. Background {#sec0005}
=============

Coronavirus Disease 2019 (COVID-19) is a new form of respiratory disorder caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)([@bib0005]). Since its first appearance and reporting in December 2019, it has infected over 462,684 cases and caused 20,834 deaths as of 26^th^ March 2020. (WHO Coronavirus disease situation reports). Patients with COVID-19 may develop acute respiratory distress syndrome and occasionally may progress to multiorgan failure([@bib0010]). Latest reports suggest that for COVID-19 the hospitalization rate is 20.7-31.4%, ICU admission rate is 4.9-11.5%, and case-fatality rate is 1.8-3.4%([@bib0015]). It is expected that COVID-19 will continue to increase and there will be a growing demand for intensive care([@bib0020]). Quick identification of potential critical patients is important in the management of this disease to prioritize health-care resources, which are under strain in practically every part of the world([@bib0025], [@bib0030]).

Cytotoxic T lymphocytes and natural killer cells are necessary for the control of viral infection. A functional exhaustion of antiviral lymphocytes is reported in COVID-19 patients([@bib0035], [@bib0040]). However, there is still limited evidence for the predictive role of lymphocyte count in predicting the severity of COVID-19. Herein, we reviewed all the literature on COVID-19 from December 2019 to 22 March to explore the possible role of lymphocyte counts in differentiating between severe and non-severe COVID-19 patients, so as to find a simple tool for quick identification of potential critical patients that will help with the clinical management of this new disease.

2. Methods {#sec0010}
==========

2.1. Literature Search and Study Selection {#sec0015}
------------------------------------------

We carried out a comprehensive systematic literature search of online databases, including PubMed, Web of Science, Cochrane, WanFang and CNKI databases from December 2019 to 22 March 2020 to identify all reported case studies in Chinese and English languages. The WanFang and CNKI databases are Chinese databases available online which can be used to find full-text articles. The following terms and their relative variants were used for literature search: "COVID-19" OR "2019 novel coronavirus infection" OR "coronavirus disease 2019" OR "2019 novel coronavirus disease" OR "coronavirus 2019" OR "2019-nCoV" OR "SARS-CoV-2" OR "COVID19" OR "coronavirus disease-19".

The title, abstract and full text of all documents identified according to this search strategy were then screened by two investigators (M.M and QW.Z). The reference list of each review and original article was reviewed for identifying other eligible reports. The inclusion criteria for the studies to be included in the meta-analysis were as follows: studies presenting the data of lymphocyte counts or information on lymphopenia in COVID-19 cases with or without severe presentation. The definition of severe COVID-19 varied in different literature. In this study we defined the "severe presentation" as a requirement for intensive care, mechanical ventilation or death which is consistent with most articles. All the search results were evaluated according to the Methodological Index Non-Randomized Studies (MINORS) statement.

2.2. Data Extraction and Quality Assessment {#sec0020}
-------------------------------------------

Data extraction and the evaluation of literature quality were conducted independently by 2 investigators (M.M and QW.Z). A Microsoft Excel database was created to record all available information, including baseline details, and rate of development of primary end point in patients with different respiratory conditions. Any disagreement was resolved by another investigator (ZY.W).

2.3. Statistical Analysis of Data {#sec0025}
---------------------------------

Microsoft Excel was used to analyze the clinical symptoms and the laboratory results. A meta-analysis was carried out using R software (version 3.6.3, available on <https://www.r-project.org>). Heterogeneity among studies was tested using the Cochran Chi-square test and *I* ^*2*^, When *I* ^*2*^  \< 50%, a fixed-effects model was used, while when *I* ^*2*^  \> 50%, a random-effects model was selected. If statistical heterogeneity was found among the results, a further sensitivity analysis was conducted to determine the source of heterogeneity. After the significant clinical heterogeneity was excluded, the randomized effects model was used for meta-analysis. Funnel plots were used to detect publication bias. P \< 0.05 was considered as statistical significance.

3. Results {#sec0030}
==========

3.1. Research Selection and Quality Assessment {#sec0035}
----------------------------------------------

Based on the described search strategy, a total of 2472 studies were found in the five online databases as described above. After removing the duplicate records, 1596 studies were retained. Furthermore, 1548 studies were excluded as they were not relevant to current meta-analysis. Full text of the remaining 48 articles was assessed for eligibility, and 35 of these were removed for various reasons. Eventually 13 studies (11 in English and 2 in Chinese) \[9-20\]were included in the analysis ([Fig. 1](#fig0005){ref-type="fig"} ). The characteristics and demographic data of the included studies are shown in [Table 1](#tbl0005){ref-type="table"} . As all the studies included in this meta-analysis were retrospective case-series, the calculation of sample size was not reported. Most studies reported the follow-up period inadequately. As a result, the overall quality of literature included in this study was not high, with MINORS scores from 10-13.Fig. 1A flow diagram of the inclusion criteria of studies eligible for meta-analysis.Fig. 1Table 1Characteristics and demographic data of the included studiesTable 1authoryearregiondistrictlanguageoutcomemean agemale n(%)Non-Severe Lymphocyte Count: Mean(SD) × 10\^9/LSevere Lymphocyte Count: Mean(SD) × 10\^9/LSevere cases/total cases ---no./total no. (%)severe cases in lymphopenia/total cases of lymphopenia ---no./total no. (%)X. Chen2020ChinaChongqingChineseComposite End Point45.3376(54.68%)1.18(0.49)0.87(0.38)31/139 (22.30%)not reportedX. Fang2020ChinaAnhuiChineseComposite End Point45.19(20.93%)1.3(0.61)0.73(0.55)24/79 (30.38%)not reportedY. Gao2020ChinaAnhuiEnglishComposite End Point44.0826(60.47%)1.07(0.4)1.2(0.42)15/43 (34.88%)not reportedW. Guan2020China30 provincesEnglishComposite End Point46.67459(58.12)not reportnot report67/1099 (6.10%)50/731 (6.84%)C. Huang2020ChinaWuhanEnglishICU49.3330(73.17%)0.93(0.31)0.47(0.5)13/41 (31.71%)11/26 (42.31%)W. Liu2020ChinaWuhanEnglishComposite End Point42.6739(50.00%)1.02(0.54)0.66(0.72)11/78 (14.10%)not reportedY. Liu2020ChinaShenzhenEnglishComposite End Point53.678(66.67%)1.56(0.99)0.63(0.42)3/12 (25.00%)3/6 (50.00%)C. Wu2020ChinaWuhanEnglishComposite End Point51.33128(63.68)1.08(0.55)0.72(0.38)84/201 (41.79%)not reportedD. Wang2020ChinaWuhanEnglishICU55.3375(54.35%)0.9(0.45)0.73(0.31)36/138 (26.09%)not reportedZ. Wang2020ChinaWuhanEnglishComposite End Point46.3332(46.38%)1.2(0.42)0.66(0.48)14/69 (20.29%)not reportedX. Yang2020ChinaWuhanEnglishDeath59.735(66.67%)0·74(0.4)0·62(0.37)32/52 (61.54)11/28 (39.29%)F. Zhou2020ChinaWuhanEnglishDeath56.33119(62.30)1.13(0.52)0.63(0.23)54/191 (28.27%)not reportedJ. Zhang2020ChinaWuhanEnglishComposite End Point56.3371(50.71%)0.87(0.45)0.73(0.38)58/140 (41.43)46/104 (44.23%)[^2]

3.2. Clinical Data {#sec0040}
------------------

The characteristics of the included studies are presented in [Table 1](#tbl0005){ref-type="table"}. The pooled clinical data of 13 studies involving 2282 cases showed that a total of 442 patients required intensive care or ventilatory support, or died. The clinical severity was defined as the composite of ICU admission, use of mechanical ventilation or death as reported in nine studies([@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0075], [@bib0090], [@bib0095], [@bib0100]), death only as reported in two studies([@bib0080], [@bib0085]) and ICU admission as reported in two studies([@bib0070], [@bib0105]). The blood tests were measured at the time of hospitalization in all studies. Eight studies reported the lymphocyte count([@bib0045], [@bib0050], [@bib0055], [@bib0065], [@bib0070], [@bib0075], [@bib0085], [@bib0100]) and one study only reported information of lymphopenia([@bib0095]). The original data was presented as the prevalence of lymphopenia in severe or non-severe COVID-19 patients. To better visualize the risk, we converted the dataset and present the data as the incidence of severe pneumonia in lymphopenia population.

3.3. Lymphocyte count and the severity of COVID-19 {#sec0045}
--------------------------------------------------

Twelve studies were included in this meta-analysis([@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085], [@bib0090], [@bib0100]). The meta-analysis for the mean difference in lymphocyte count showed an overall significant reduction of 0.31 × 10^9^/L in the severe COVID-19 group compared to the non-severe group (random effects model, CI: -0.42 to -0.19 × 10^9^/L). The overall heterogeneity in this meta-analysis was high (*I* ^*2*^  = 76%; p \< 0.01, [Fig. 2](#fig0010){ref-type="fig"}A). Sensitivity analysis revealed that this heterogeneity was not a result from an individual study. Funnel plot showed no publication bias in this analysis ([Fig. 2](#fig0010){ref-type="fig"}B).Fig. 2Forest plot and funnel plot of all outcomes.Fig. 2

3.4. Lymphopenia and the severity of COVID-19 {#sec0050}
---------------------------------------------

Five studies reported the relationship between lymphopenia and the severity of COVID-19([@bib0055], [@bib0060], [@bib0075], [@bib0090], [@bib0095]). Lymphopenia was defined as a lymphocyte count of less than 1.1 × 10^9^/L in four studies([@bib0055], [@bib0060], [@bib0080], [@bib0090]), and as less than 1.5 × 10^9^/L in one([@bib0095]). The pooled OR as summarized in [Fig. 2](#fig0010){ref-type="fig"}C shows that the presence of lymphopenia results in an approximately 3-fold increased risk of severe COVID-19 (Random effects model, OR = 2.99, 95% CI: 1.31-6.82). The heterogeneity among the different studies was high (*I* ^*2*^  = 60%, p = 0.04). A sensitivity analysis by excluding each study was performed, showing the study from Z. Wang was the major source of heterogeneity. After excluding this study, the *I* ^*2*^ of heterogeneity reduced to 48%, the OR of lymphopenia was 2.17 (95% CI: 1.0126-4.6812). The funnel plot indicated no publication bias inside this study ([Fig. 2](#fig0010){ref-type="fig"}D).

4. Discussion {#sec0055}
=============

This meta-analysis included the latest studies of COVID-19 from December 2019 to 22 March 2020 published in the English and Chinese language, showing that patients with severe COVID-19 displayed a lymphocyte count reduction compared with the non-severe COVID-19 group. Lymphopenia, defined as a lymphocyte count of less than 1.5 × 10^9^/L, is associated with a 3-fold increased risk of severe COVID-19 infection.

The lack of awareness of severity of disease in the early stages of COVID-19 coupled with the high infectivity of the virus has led to a dramatic increase in the number of patients and relatively high fatality rates worldwide. A cheap, easily acquired biomarker is needed to identify severe disease among hospitalized patients at early stages. According to our results, lymphocyte count and lymphopenia may serve as a rapid tool that can quickly identify COVID-19 patients with more severe clinical presentation. Previous studies observed that lymphopenia is a common observation in patients with severe acute respiratory syndrome (SARS) caused by SARS virus with reported prevalence of 69.6%-54%([@bib0110], [@bib0115]). Lymphopenia is quite notable in SARS infection([@bib0120]). SARS infection may either directly suppress bone marrow or induce an immune-mediated destruction of lymphocytes resulting in lymphopenia ([@bib0125]). SARS-COV-2 might share a similar inner mechanism with SARS virus, including direct infection and destruction of lymphocytes ([@bib0130]) and cytokine-mediated lymphocyte destruction ([@bib0135], [@bib0140], [@bib0145]).

The main drawback of this meta-analysis is the heterogeneity of included cases. All the included studies were retrospective case series as no data from either prospective observation study or randomized trials are available. The patients in different studies might be at different stages of disease. Furthermore, the different definitions of severity of COVID-19 and the discrepancy in the cut-offs for lymphopenia, which can be partially mitigated by considering lymphocyte count of less than 1.5 × 10^9^/L as lymphopenia, might be one of the reasons for the heterogeneity.

In addition, another drawback of our study is that there is no data relating to fluctuations of lymphocyte counts on the disease course, which is significant to the detection of COVID-19 clinical course. So, it is too early to draw the conclusion that lymphopenia is related to deterioration of COVID-19. A recent research study with small sample size showed the dynamic changes of lymphocyte counts could predict the deterioration of COVID-19, yet studies with large sample size are still lacking in this field([@bib0150]).

Due to the extremely rapid spread of COVID-19 worldwide, waiting for the results from prospective studies will delay the understanding of this novel disease, as a result of which there may be a delay in the clinical management of patients. Even in light of these limitations, the result of this meta-analysis show that the presence of lymphopenia in the evolution of COVID-19 may help to rapidly identify patients at risk of severe pneumonia and worse outcomes. Further studies should focus on the time-line of lymphopenia development, severity of COVID-19 and ARDS, which may confirm our findings about the relationship between lymphopenia and severity of COVID-19.

5. Conclusion {#sec0060}
=============

Lymphopenia is a prominent part of severe COVID-19 and a lymphocyte count of less than 1.5 × 10^9^/L may be useful in predicting the severity of clinical outcomes. Further studies are needed to focus on lymphocyte changes in COVID-19 to confirm the predictive ability of lymphopenia in COVID-19.
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